Quality framework

Upstream manufacturing

All compounds are sourced from manufacturers operating under International Conference on Harmonisation (ICH) Q7 Good Manufacturing Practice — the same framework adopted by the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), and the UK Medicines and Healthcare products Regulatory Agency (MHRA) for active pharmaceutical ingredient manufacturing.

Independent verification

Every released batch undergoes independent High-Performance Liquid Chromatography (HPLC) analysis at a third-party analytical laboratory in the United States.

• Method: HPLC with UV detection at λ = 214 nm
• Acceptance criterion: ≥98% peak-area purity
• Reference standards: United States Pharmacopeia (USP-NF), European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP)

Researchers may request the upstream manufacturer's Certificate of Analysis and the independent HPLC chromatogram for any batch through their research account.

Delivery and storage

Compounds ship in lyophilized (freeze-dried) form and remain ambient-temperature stable in transit. Refrigeration is required only after reconstitution, in line with each compound's reconstitution protocol.

• Within the UAE: 1–3 business days
• International (B2B and institutional, scheduled late 2026): 3–7 business days

International, institutional, clinic, and GCC distributor enquiries: info@uaewellnesslab.com.